3H Medi Solution has selected Thread for expanding the delivery of decentralised clinical trials (DCTs) and enhancing access to research for Japanese patients.

The deep recruitment, home visit support of 3H Medi Solution, along with overall clinical study delivery expertise and Thread’s technology platform and consulting services, will provide improved offerings to clients.

This offering is aimed at powering modern, patient-centered clinical research in the country.

It also provides the opportunity for sponsors in Japan to engage consultants for operational service delivery, patient-centred design, and technology platform support for eCOA and DCT solutions.

3H Medi Solution CEO Sho Ando said: “The selection of Thread as our partner is an important step in bringing more research opportunities to patients in Japan.

“The ability to apply truly modern study designs, including decentralised elements that help create better experiences for patients, will enable new care options for patients while producing better and safer medicines.”

The company is currently driving the enrolment of over 10,000 participants annually.

Thread’s flexible and innovative study platform will be beneficial for patients, study sites, and sponsors.

This platform will be backed by local, in-language support from 3H Medi Solution professionals.

Thread co-founder and CEO John Reites said: “Consistent with our mission to bring next-generation research approaches to everyone, everywhere, we are excited to work with 3H Medi Solution to offer patients and clinicians in Japan enhanced access to clinical research opportunities.

“Expanding the availability of decentralised research solutions in Japan provides an opportunity to support better representation and inclusion of patients in research.”

Last month, Sanofi enlisted Thread as a global DCT provider under a five-year collaboration deal.

Decentralised Clinical Trial coverage in Clinical Trials Arena is supported by Huma.

Editorial content is independently produced and follows the highest standards of journalistic integrity. Topic sponsors are not involved in the creation of editorial content.